Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Astellas is spinning up a new attack on a cancer market, paying $175 million to buy Propella Therapeutics and its clinical-phase challenger to Johnson & Johnson’s fast-fading prostate cancer blockbuster Zytiga.